SGLTs (Sodium-dependent glucose cotransporters) are a family of glucose transporters and contribute to glucose reabsorption.SGLT1 and SGLT2, which belong to the SLC5A gene family, are the two most well-known members of the SGLT family. The two transporters play two major roles in maintaining glucose homeostasis: first, via SGLT1, they absorb glucose from the diet in the small intestine, and second, through SGLT2 and, to a lesser extent, SGLT1, they re-absorb the filtered glucose in the kidney's tubular system, which puts glucose back into the bloodstream and stops urine glucose loss. For diabetes and cardiomyopathy, SGLT1 and SGLT2 have been suggested as a novel therapeutic approach.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V12578 | Bexagliflozin | 1118567-05-7 | Bexagliflozin (formerly known as THR 1442; EGT1442; EGT-1442; Brenzavvy) is a potent and selective SGLT2 inhibitor with antidaibetic activity. |
|
V1499 | Canagliflozin (JNJ 28431754) | 842133-18-0 | Canagliflozin (formerly TA-7284; JNJ-24831754ZAE; JNJ 28431754-AAA; JNJ-28431754; brand name Invokana)is a highly potent and selective SGLT2 (sodium-glucose transport protein) inhibitor with anti-diabetic activity. |
|
V78619 | Canagliflozin-d6 (JNJ 28431754-d6) | Canagliflozin-d6 is the deuterated form of Canagliflozin. | |
|
V28640 | Dapagliflozin ((2S)-1,2-propanediol hydrate) | 960404-48-2 | Dapagliflozin ((2S)-1,2-propanediol hydrate) is the S-isomer of Dapagliflozin 1,2-propanediol hydrate, which is an antidiabetic drug used to treat diabetes mellitus (DM). |
|
V1498 | Dapagliflozin (BMS-512148) | 461432-26-8 | Dapagliflozin (formerly known as BMS-512148; trade names Farxiga in the US and Forxiga in the EU) is a potent and selective hSGLT2 (sodium-glucose transport proteins) inhibitor with anti-diabetic activity. |
|
V1500 | Empagliflozin (BI 10773) | 864070-44-0 | Empagliflozin (formerly also known as BI1-0773; CE0108; CS0940; PB23119; VA10802; AJ93046; trade name: Jardiance) is a potent and selective SGLT-2 (sodium glucose cotransporter-2) inhibitor with anti-diabetic activity. |
|
V74236 | Empagliflozin-d4 (Empagliflozin-d4; BI 10773-d4) | 2749293-95-4 | Empagliflozin-d4 is the deuterium labelled form of Empagliflozin. |
|
V74235 | Enavogliflozin (DWP-16001) | 1415472-28-4 | Enavogliflozin (DWP-16001), an antidiabetic active molecule, is an orally bioactive, first-in-class, selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor. |
|
V74243 | Ertugliflozin-d5 (PF-04971729-d5) | 1298086-22-2 | Ertugliflozin-d5 is the deuterated form of Ertugliflozin. |
|
V74237 | Luseogliflozin hydrate (TS 071 hydrate) | 1152425-66-5 | Luseogliflozin (TS 071) hydrate is a selective, orally bioactive second-generation sodium-glucose cotransporter 2 (SGLT2) inhibitor (antagonist) with IC50 of 2.26 nM. |
|
V4942 | Phloretin | 60-82-2 | Phloretin (also known as NSC 407292 and RJC 02792), a naturally occuring dihydrochalcone flavonoid mainly found in fruit, leaves, and roots of apple tree, inhibits a variety of transporters such as the monocarboxylate transporters MCT1 and MCT2 (IC50 = 28 and 14 µM, respectively). |
|
V5117 | Phlorizin (Floridzin; NSC 2833) | 60-81-1 | Phlorizin (phloridzin), a glucoside of phloretin which is a dihydrochalcone and a family of bicyclic flavonoids, is a potent and non-selective competitive SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. |
|
V74238 | Rongliflozin (DJT1116PG) | 2648020-91-9 | Rongliflozin (DJT1116PG) is a selective, orally bioactive inhibitor of sodium-glucose cotransporter-2 (SGLT-2). |
|
V74240 | SGLT1/2-IN-1 | 1673514-65-2 | SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor. |
|
V74239 | SGLT1/2-IN-2 | 2387812-73-7 | SGLT1/2-IN-2 showed potent dual (bifunctional) inhibitory activity (IC50 = 96 nM for SGLT1 and IC50 = 1.3 nM for SGLT2). |
|
V1501 | Sotagliflozin (LX4211) | 1018899-04-1 | Sotagliflozin (formerly known as LP-80203; LX4211; LP80203; LX-4211; Zynquista), an antidiabetic drug approved for treating type 1 diabetes in EU, is a potent, orally bioavailable, and dual SGLT1/SGLT2 inhibitor with antidiabetic activity. |
|
V74244 | Tofogliflozin (CSG452) | 903565-83-3 | Tofogliflozin (CSG-452) is a highly efficient and selective inhibitor of SGLT2, with Kis of 2.9, 14.9 and 6.4nM for human, rat and mouse SGLT2 respectively. |
|
V74245 | Velagliflozin proline | 1539295-26-5 | Velagliflozin proline is an orally bioavailable sodium-glucose cotransporter 2 (SGLT2) inhibitor (antagonist) with antidiabetic activity. |
|
V74241 | Velagliflozin proline hydrate | 1661838-94-3 | Velagliflozin proline hydrate is the clinical form of Velagliflozin. |
|
V74242 | YM543 free base | 655237-16-4 | YM543 free base is an orally bioavailable sodium-glucose cotransporter (SGLT) 2 inhibitor. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
